• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A New Health Networking Infrastructure on Cancer Is Taking Shape in Europe: A Not-to-Miss Opportunity for the EU Regulatory System.

作者信息

Casali Paolo Giovanni, Capri Stefano

机构信息

Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy;

Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, 20100 Milan, Italy.

出版信息

J Mark Access Health Policy. 2025 Apr 28;13(2):18. doi: 10.3390/jmahp13020018. eCollection 2025 Jun.

DOI:10.3390/jmahp13020018
PMID:40416335
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12101281/
Abstract
摘要

相似文献

1
A New Health Networking Infrastructure on Cancer Is Taking Shape in Europe: A Not-to-Miss Opportunity for the EU Regulatory System.欧洲正在形成一个新的癌症健康网络基础设施：欧盟监管体系不容错过的机遇。
J Mark Access Health Policy. 2025 Apr 28;13(2):18. doi: 10.3390/jmahp13020018. eCollection 2025 Jun.
2
Health networking on cancer in the European Union: a 'green paper' by the EU Joint Action on Networks of Expertise (JANE).欧盟癌症健康网络：欧盟专业知识网络联合行动（JANE）发布的“绿皮书”
ESMO Open. 2025 Feb;10(2):104126. doi: 10.1016/j.esmoop.2024.104126. Epub 2025 Jan 27.
3
Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project.迈向欧洲放射治疗基础设施和人员配备需求的循证指南：ESTRO QUARTS项目
Radiother Oncol. 2005 Jun;75(3):355-65. doi: 10.1016/j.radonc.2004.12.007. Epub 2005 Mar 16.
4
Towards an EU legislation on the right to be forgotten to access to financial services for cancer survivors.关于欧盟遗忘权立法以获取癌症幸存者金融服务的研究
Eur J Cancer. 2022 Feb;162:133-137. doi: 10.1016/j.ejca.2021.12.001. Epub 2022 Jan 3.
5
Twentieth anniversary of the European Union health mandate: taking stock of perceived achievements, failures and missed opportunities - a qualitative study.欧盟健康指令二十周年：对感知到的成就、失败和错失的机会进行评估——一项定性研究。
BMC Public Health. 2013 Nov 14;13:1074. doi: 10.1186/1471-2458-13-1074.
6
Empowering cancer research in Europe: the EUCAIM cancer imaging infrastructure.助力欧洲癌症研究：欧盟癌症成像基础设施（EUCAIM）
Insights Imaging. 2025 Feb 24;16(1):47. doi: 10.1186/s13244-025-01913-x.
7
Integrating technical and political views for a sustainable European Distributed Infrastructure on Population Health.整合技术与政治观点，构建可持续的欧洲人口健康分布式基础设施。
Arch Public Health. 2022 Jan 17;80(1):29. doi: 10.1186/s13690-022-00790-w.
8
Identification of autosomal cis expression quantitative trait methylation (cis eQTMs) in children's blood.鉴定儿童血液中常染色体顺式表达数量性状甲基化（cis-eQTMs）。
Elife. 2022 Mar 18;11:e65310. doi: 10.7554/eLife.65310.
9
Anniversary Oncology Days in Paris.巴黎周年肿瘤日。
Exp Oncol. 2023 Dec 28;45(3):273-274.
10
Adapting, implementing and evaluating a navigation intervention for older people with cancer and their family caregivers in six countries in Europe: the Horizon Europe-funded EU NAVIGATE project.在欧洲六个国家为老年癌症患者及其家庭护理人员调整、实施和评估一项导航干预措施：由“地平线欧洲”资助的欧盟导航项目。
Palliat Care Soc Pract. 2024 Oct 17;18:26323524241288873. doi: 10.1177/26323524241288873. eCollection 2024.

本文引用的文献

1
Health networking on cancer in the European Union: a 'green paper' by the EU Joint Action on Networks of Expertise (JANE).欧盟癌症健康网络：欧盟专业知识网络联合行动（JANE）发布的“绿皮书”
ESMO Open. 2025 Feb;10(2):104126. doi: 10.1016/j.esmoop.2024.104126. Epub 2025 Jan 27.
2
Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis.基于不成熟生存数据首次获美国食品和药物管理局批准的癌症药物的总生存获益：一项回顾性分析。
Lancet Oncol. 2024 Jun;25(6):760-769. doi: 10.1016/S1470-2045(24)00152-9. Epub 2024 May 13.
3
Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study.1995 年至 2020 年间欧洲药品管理局批准的肿瘤药物的附加获益和收益：回顾性队列研究。
BMJ. 2024 Feb 28;384:e077391. doi: 10.1136/bmj-2023-077391.
4
Data protection and research in the European Union: a major step forward, with a step back.欧盟的数据保护与研究：向前迈出一大步，却又后退一步。
Ann Oncol. 2021 Jan;32(1):15-19. doi: 10.1016/j.annonc.2020.10.472. Epub 2020 Oct 21.
5
Networking in rare cancers: What was done, what's next.罕见癌症的交流网络：已做了什么，下一步是什么。
Eur J Surg Oncol. 2019 Jan;45(1):16-18. doi: 10.1016/j.ejso.2018.03.030. Epub 2018 Apr 12.
6
Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan.欧盟、美国和日本的药品许可和报销
Clin Pharmacol Ther. 2016 Dec;100(6):626-632. doi: 10.1002/cpt.505. Epub 2016 Oct 17.
7
Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper.欧洲罕见癌症临床研究的方法学建议：一份欧洲共识立场文件
Ann Oncol. 2015 Feb;26(2):300-6. doi: 10.1093/annonc/mdu459. Epub 2014 Oct 1.
8
Rare cancers are not so rare: the rare cancer burden in Europe.罕见癌症并不罕见：欧洲的罕见癌症负担。
Eur J Cancer. 2011 Nov;47(17):2493-511. doi: 10.1016/j.ejca.2011.08.008. Epub 2011 Oct 25.